Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
Authors
Keywords
Blood plasma, Mouse models, Kidneys, Urine, Oral administration, Heart, Phase II clinical investigation, Quality control
Journal
PLoS One
Volume 8, Issue 3, Pages e57631
Publisher
Public Library of Science (PLoS)
Online
2013-03-06
DOI
10.1371/journal.pone.0057631
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Urinary Globotriaosylsphingosine-Related Biomarkers for Fabry Disease Targeted by Metabolomics
- (2012) Christiane Auray-Blais et al. ANALYTICAL CHEMISTRY
- LC–MS/MS analysis of plasma lyso-Gb3 in Fabry disease
- (2012) Michel Boutin et al. CLINICA CHIMICA ACTA
- Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice
- (2012) Elfrida R Benjamin et al. MOLECULAR THERAPY
- Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
- (2012) Saskia M. Rombach et al. PLoS One
- Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage Disorders
- (2011) Kenneth J. Valenzano et al. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
- A pharmacogenetic approach to identify mutant forms of α-galactosidase a that respond to a pharmacological chaperone for Fabry disease
- (2011) Xiaoyang Wu et al. HUMAN MUTATION
- Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry
- (2011) Ralf Krüger et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies
- (2011) Johannes M. F. G. Aerts et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice
- (2011) Brandon Durant et al. JOURNAL OF LIPID RESEARCH
- Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
- (2011) D. G. Warnock et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease
- (2010) Tadayasu Togawa et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma globotriaosylsphingosine: Diagnostic value and relation to clinical manifestations of Fabry disease
- (2010) S.M. Rombach et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy
- (2010) Mariëlle J. van Breemen et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
- (2010) Christiane Auray-Blais et al. CLINICA CHIMICA ACTA
- Plasma globotriaosylsphingosine as a biomarker of Fabry disease
- (2010) Tadayasu Togawa et al. MOLECULAR GENETICS AND METABOLISM
- Fabry disease
- (2010) Dominique P Germain Orphanet Journal of Rare Diseases
- The pharmacological chaperone 1-deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines
- (2009) E. R. Benjamin et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Agalsidase Alfa and Kidney Dysfunction in Fabry Disease
- (2009) M. West et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease
- (2009) Richie Khanna et al. MOLECULAR THERAPY
- Early therapeutic intervention in females with Fabry disease?
- (2008) Derralynn A Hughes ACTA PAEDIATRICA
- Preclinical Efficacy and Safety of 1-Deoxygalactonojirimycin in Mice for Fabry Disease
- (2008) S. Ishii et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period
- (2008) Koichi Ogawa et al. MOLECULAR GENETICS AND METABOLISM
- Elevated globotriaosylsphingosine is a hallmark of Fabry disease
- (2008) J. M. Aerts et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease
- (2007) Christiane Auray-Blais et al. MOLECULAR GENETICS AND METABOLISM
- Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
- (2007) William R. Wilcox et al. MOLECULAR GENETICS AND METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search